Trial
NCT05155085
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Allakos Inc.
Collaborators
—
Condition
Atopic Dermatitis
Intervention
AK002
Why stopped
No longer pursuing development
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-15